Mechanism of Action
KPV replicates the anti-inflammatory activity of alpha-msh/" class="wiki-internal-link">alpha-MSH at reduced molecular size with enhanced GI stability.
MC1R Agonism and NF-kB Inhibition
KPV activates MC1R on macrophages, dendritic cells, and intestinal epithelial cells, triggering cAMP elevation that inhibits NF-kB nuclear translocation. NF-kB is the master regulator of pro-inflammatory gene expression, its inhibition reduces TNF-alpha, IL-1beta, IL-6, and IL-8 production across multiple cell types.[1]Intestinal Epithelial Barrier Protection
KPV acts directly on intestinal epithelial cells (IECs), upregulating tight junction proteins (occludin, ZO-1) and reducing permeability. In colitis models, KPV treatment restores barrier function and reduces mucosal inflammation independently of systemic effects.[2]Oral Delivery Advantage
Unlike most peptides, KPV's small size and proline-containing sequence resist GI protease degradation. It is transported across intestinal epithelium via PepT1 (peptide transporter 1), the same high-capacity transporter used for dipeptides and tripeptides. This makes oral dosing effective for gut-targeted anti-inflammatory applications.[3]Research Overview
Inflammatory Bowel Disease
Most StudiedKPV is primarily studied for IBD. In DSS-induced and TNBS-induced colitis models, KPV reduces colon inflammation, preserves epithelial barrier, and lowers inflammatory cytokines. Oral, rectal, and nanoparticle KPV formulations all show efficacy. Orally administered nanoparticle KPV has been evaluated for targeted IBD delivery.[2]
Systemic Anti-inflammatory Effects
Strong EvidenceSubcutaneous KPV suppresses LPS-induced systemic inflammation, reducing fever and cytokine storm. In sepsis models, KPV reduces organ damage scores. These systemic effects complement its local gut activity when injected rather than administered orally.[1]
Skin Inflammation
Moderate EvidenceKPV shows anti-inflammatory efficacy in dermatitis and psoriasis models. Topical KPV formulations reduce inflammatory markers in skin equivalents. The dual skin/gut anti-inflammatory activity reflects MC1R expression at both sites.[4]
Calculate your KPV dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| IBD / gut inflammation (oral) | 500 µg | Twice daily (oral capsule) | Oral |
| Systemic anti-inflammatory | 100–250 µg | Once daily | Subcutaneous |
| BPC-157 gut stack (oral) | 500 µg KPV + 250 µg BPC-157 | Twice daily | Oral |
| Conservative start | 250 µg | Once daily | Oral or SC |
Oral KPV can be taken with or without food for gut targeting. Subcutaneous administration for systemic anti-inflammatory effects. The oral BPC-157 + KPV combination is a common gut healing stack, both stable to gastric acid and effective by oral route.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
KPV has a favorable safety profile as a fragment of an endogenous peptide (alpha-MSH).
No significant adverse effects: Preclinical and limited human data show excellent tolerability. As a fragment of endogenous alpha-MSH, systemic safety is considered high.
Oral route advantage: Oral dosing avoids injection-site reactions and systemic peak concentrations associated with subcutaneous injection.
No appetite stimulation: Unlike full alpha-MSH or Melanotan II, the C-terminal KPV fragment does not significantly activate appetite or tanning pathways at research doses.
No FDA approval: Research compound only.
References
- [1]Lipton JM, Catania A. "Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH." Immunol Today. 1997;18(3):140-145.
- [2]Kannengiesser K, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine experimental colitis." Inflamm Bowel Dis. 2008;14(3):324-331.
- [3]Laroui H, et al. "Dextran sodium sulfate (DSS) induces a colitis in mice that is location- and time-dependent." PLoS One. 2012;7(1):e29783.
- [4]Bohm M, Luger TA. "The pilosebaceous unit is part of the skin immune system." Dermatology. 1998;196(1):75-79.